Pharmaceutical composition and method for hypermetabolic weight loss |
| The present invention relates to a device, pharmaceutical composition and method for metabolizing ... |
|
Method for manufacturing glycoproteins having human-type glycosylation |
| What is claimed is: 1. A method of manufacturing a glycoprotein having a sugar chain, comprising a ... |
|
Dimeric fluorescent energy transfer dyes comprising asymmetric cyanine azole-indolenine chromophores |
| What is claimed is: 1. A compound of the formula: ##STR2## wherein: a is from 0 to 6,: b is from 0 ... |
|
Nucleic acid analogue induced transcription of double stranded DNA |
| We claim: 1. A method of transcribing RNA, using a double-stranded DNA as a template, comprising: (... |
|
Peptide nucleic acid combinatorial libraries |
| OF THE INVENTION The synthesis of peptide nucleic acids (also known as PNA) via preformed monomers ... |
|
Nucleic acid-containing polymerizable complex |
| OF THE INVENTION The present invention is based on the development of a polymerizable complex ... |
|
Chiral peptide nucleic acids and methods for preparing same |
| OF THE INVENTION Specific sequence recognition of DNA or RNA is of increasing importance for the ... |
|
Capillary electrophoretic detection of nucleic acids |
| OF THE PREFERRED EMBODIMENTS This invention provides novel methods for the detection and isolation ... |
|
PNA diagnostic methods |
| The present invention provides methods for detecting nucleic acid sequences and/or determining ... |
|
|
Polymer microparticles for drug delivery
| Details |
Inventors: Yeh, Ming-Kung; Coombes, Alan Gerald; Jenkins, Paul George; Davis, Stanley Stewart;
Assignee: Danbiosyst UK Limited (Nottingham, GB)
Primary Examiner: Azpuru; Carlos A.
Assistant Examiner:
Attorney, Agent or Firm: Arnall Golden & Gregory, LLP
Provided are biodegradable microparticles, which exhibit a linear release profile of active agent, and methods for making the microparticles. The microparticles include a mixture of a biodegradable polymer, a water soluble polymer, and an active agent. Preferred biodegradable polymers include lactide homopolymers or copolymers of lactide and glycolide, and preferred water soluble polymers include poly(ethylene glycol) (PEG) or PEG copolymers. The microparticles are made using an emulsion/solvent extraction method, in which the continuous phase of the secondary emulsion contains an organic solvent that is miscible with the organic solvent in the primary emulsion. |
|
DETAILED DESCRIPTION OF THE INVENTION The term microparticle is used herein to include nanoparticles. The microparticles preferably have a size in the range 10 nm to 200. mu. m. The water-soluble polymer is preferably soluble in both water and dichloromethane (DCM). The term "biodegradable polymer" is used herein to include polymeric systems which can degrade into low molecular weight compounds which are known to be involved normally in metabolic pathways. The term also includes polymer systems which can be attached in the biological milieu so that the integrity of the system, and in some cases of the macromolecules themselves, is affected and gives fragments or other degradation by-products which can move away from their site of action, but not necessarily from the body. The ratio of biodegradable polymer to water-soluble polymer is in the range 99. 9:1. 0 to 10:90, more preferably 90:10 to 10:90. Suitable biodegradable polymers for producing the microparticles are polyesters such as polylactide, polyglycolide, copolymers of lactide and glycolide, polyhydroxybutyrate, polycaprolactone, copolymers of lactic acid and lactone, copolymers of lactic acid and PEG, copolymers of a-hydroxy acids and . alpha. -amino acids (polydepsipeptides), polyanhydrides, polyorthoesters, polyphosphazenes, copolymers of hydroxybutyrate and hydroxyvalerate, poly(ethylene carbonate), copoly(ethylene carbonate). polyethylene terephthalate or mixtures of these polymers. The preferred resorbable/biodegradable polymers are lactide homopolymers poly(L-lactide), poly(D,L-lactide), and copolymers of lactide and glycolide such as 50:50 poly(DL lactide co-glycolide)(PLG). The PLG preferably has a molecular weight in the range 5-100 kD. While poly(ethylene glycol) (PEG) is the preferred water soluble polymer for mixing with the biodegradable polymer, other suitable water soluble polymers include poly(oxyethylene oxide)(PEO), poly(oxyethylene)-poly(oxypropylene) ?PEO-PPO! block copolymers such as tri-block PEO-PPO-PEO copolymers (POLOXAMERS
|
| Related patents |
|
|
Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
The present invention provides bioactive agents encapsulated in a rapidly releasing polymeric composition capable of inducing or potentiating an immune response and ...
|
|
|
Disaccharide derivatives for treating hyperglycaemia
The invention claimed is: 1. A drug composition comprising an active ingredient and a carrier in which said active ingredient is an amide or alkyl ester of an oxidized ...
|
|
|
Gene expression profiles in liver cancer
1. A method of diagnosing hepatocellular carcinoma in a human patient, compnsing: (a) detecting the level of expression in a tissue sample of ten or more genes from T...
|
|
|
Endovascular cardiac venting catheter and method
The present invention is directed to an endovascular approach for preparing a patient's heart for cardiac procedures which does not require a grossly invasive ...
|
|
|
Bone morphogenic protein-5(BMP-5) and DNA encoding same
OF THE INVENTION Purified human BMP-5 proteins are produced by culturung a host cell transformed with the DNA sequence of Table III. The expressed BMP-5 proteins are ...
|
|
|
Adipocyte-specific protein homologs
Within one aspect of the invention is provided an isolated polypeptide comprising a sequence of amino acid residues that is at least 80% identical to SEQ ID NO:2, ...
|
|
|
LSR receptor, activity, cloning, and uses for diagnosing, preventing and/or treating obesity and related risks or complications
The LSR receptor The invention relates to a purified LSR receptor (<<Lipolysis Stimulated Receptor>>), preferably hepatic, consisting of at least one .alpha....
|
|
|
Multi-functional chimeric hematopoietic receptor agonists
1. A hematopoietic protein comprising; an amino acid sequence of the formula: Met-1 R1-L1-R2, Met-2 Ala-1 P1-L1-R2, Ala-1 R1-L1-R2, R1-L1-R2, Met-1 R2-L1-R1, Met-2 Ala-1 ...
|
|
|
Composition and method for treatment and prevention of traumatic synovitis and damage to articular cartilage
OF THE INVENTION Additional objects, advantages and other novel features of the invention will be set forth in part in the description that follows and in part will ...
|
|
|
DNA sequences comprising dystrophin minigenes and methods of use thereof
The present invention provides dystrophin minigenes that are significantly reduced in size without compromising essential functions in protecting muscles from dystrophic ...
|
|
|